Controversial patient deaths in CAR-T study spur a class action suit against Juno
Juno continues to feel the fallout from its painful, and very brief, trial hold for its lead CAR-T JCAR015. In a newly filed class action suit, investors say that they were purposefully misled by Juno executives, who kept quiet about the first suspicious patient death in May.
According to the suit, the company was prompted to tell regulators about the death due to a cerebral edema. But when it came to its June earnings announcement, the company stayed silent about any deaths, sticking to evidence of grade 3 neurotoxicity. And with the company touting its results, CEO Hans Bishop cashed out of $8.6 million in shares.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.